Novartis(NVSEF)

BASEL, SwitzerlandPharmaceutical2 H-1B visas (FY2023)

Focus: Novartis is a global pharmaceutical giant headquartered in Basel, Switzerland, with 78,000 employees and a diversified portfolio across small molecules, vaccines, and biologics. The company commands a major market position across oncology, immunology, neuroscience, cardiovascular, and ophthalmology.

Oncology Immunology Neuroscience Cardiovascular

Profile data last refreshed 18h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Employees

78,000

Open Jobs

866+291 this month

Hot — 1086 jobs added in 30d

Net +291 (1086 new, 795 removed). Aggressive expansion phase.

5 recent layoff filings (12 mo) — 686 affected

7/1/2026 — East Hanover, NJ · 322 affected · Layoff
5/1/2026 — East Hanover, NJ · 76 affected · Layoff
4/1/2026 — East Hanover, NJ · 60 affected · Layoff
+2 more

Source: state DOL filings via Big Local News

Should You Work at Novartis?

AI assessment

Novartis offers world-class drug development exposure and stable platform diversity, but career security is tempered by ongoing large-scale layoffs and meaningful near-term revenue cliff risk.

Why Work Here

Access to blockbuster-stage programs: ENTRESTO (peak, $3.4B Part D spend) and multiple oncology assets (KISQALI, TASIGNA, MEKINIST) with patent protection extending to 2031–2038

Data completeness

6/9 — Partial

Company HealthWatch

Pipeline

Early-stage

50 total

LOE Risk

6 imminent

AFINITOR

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

ENTRESTO

Angiotensin 2 Receptor Blocker

$3.4B

Peak9.6yr

Flagship cardiovascular asset dominating 61% of company revenue; protected until 2036.

Help build intelligence for Novartis

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diverse therapeutic platform spanning vaccines (influenza Phase 3, meningococcal Phase 3, GBS Phase 2), small molecules, and biologics across five major therapeutic areas

Active hiring across 621 open roles, particularly in Commercial (160 roles), R&D (75), and Business Development (59), signaling continued expansion initiatives

Watch Out For

Severe ongoing restructuring: 2,531+ employees affected across 16 WARN filings since 2023, with largest wave (680 spin-off restructuring in March 2024, 427–322-person layoffs through mid-2026) concentrated in East Hanover, NJ
Patent cliff looming: $731M revenue at risk between 2028 and 2031 (PROMACTA $558M LOE 2028-02, MEKINIST $173M LOE 2031-04), requiring rapid pipeline maturation to offset decline

Generated by Claude from Novartis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

PROMACTA

Thrombocytopenia

$558M

LOE Approaching1.4yr

Second-largest patent cliff candidate with $558M Part D spend; loses exclusivity February 2028.

TASIGNA

Chronic Myeloid Leukemia

$395M

Peak6.0yr

Oncology franchise cornerstone; patent protected until October 2032.

KISQALI

Breast Cancer

$371M

Peak10.1yr

CDK4/6 inhibitor in peak revenue generation; protected until October 2036.

MEKINIST

Melanoma

$173M

Peak4.6yr

MEK inhibitor with dual LOE dates; first cliff April 2031 threatens $173M revenue.

MEKINIST

Melanoma

$173M

Peak7.4yr

Secondary patent expiration February 2034 for alternate indication; revenue at risk spreads across two dates.

GLATIRAMER ACETATE

Relapsing forms of multiple sclerosis

$151M

Post-LOE

Generic immunomodulator for MS; post-exclusivity asset generating $151M via brand maintenance and formulation advantages.

TAFINLAR

Melanoma

$147M

Peak12.3yr

BRAF inhibitor with longest remaining patent protection (December 2038); long tail stability.

PIQRAY

Breast Cancer

$138M

Peak6.6yr

PI3K inhibitor in growth; patent protected until April 2033.

GILENYA

Multiple Sclerosis

$125M

Peak6.0yr

S1P receptor modulator; immunology franchise contributor with protection until September 2032.

Pipeline & Clinical Trials

Lutetium-177 DOTATATE

Neuroendocrine Tumor

N/A

Clinical Trials (1)

NCT05816720Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)

N/A

NewSpringForMe digital solution

Hematologic Diseases

N/A

IVA group

The Injection Burden

N/A

Clinical Trials (1)

NCT02126904Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept

N/A

Human Urine Sample Collection for Alport Nephropathy Biomarker Studies

Alport Syndrome

N/A

Clinical Trials (1)

NCT01602835Human Urine Sample Collection for Alport Nephropathy Biomarker Studies

N/A

Treatment

Cancer

N/A

Clinical Trials (5)

NCT00136851Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension

Phase 4

NCT00143026Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States

Urine, DNA and Clinical Information Collection From Patients With Alport Nephropathy.

Alport Nephropathy

N/A

Clinical Trials (1)

NCT03074357Urine, DNA and Clinical Information Collection From Patients With Alport Nephropathy.

N/A

tobacco smoking substitution products

HIV

N/A

Clinical Trials (1)

NCT06789692Reduce Tobacco Use in People Living With HIV in Switzerland

N/A

other disease-modifying therapy

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT01442194Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

N/A

No intervention

Kidney Diseases

N/A

Clinical Trials (3)

NCT05407740"Association of Proteinuria and Progression of Kidney Dysfunction in Sickle Cell Disease"Disease

N/A

NCT04948671Primary Hyperparathyroidism and Gut Microbiota

N/A

real anodal transcranial direct current stimulation

Real tDCS

N/A

Clinical Trials (1)

NCT03959462Supporting Decisions With Transcranial Direct Current Stimulation in Healthy Young and Elderly Individuals

N/A

Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML

MDS

N/A

Clinical Trials (1)

NCT06267898Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML

N/A

Observational Registry Study of Renal Transplant Patients

Kidney Transplant

N/A

Clinical Trials (1)

NCT01284257Observational Registry Study of Renal Transplant Patients

N/A

Secondary Use of PARALLEL-HF Data

Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)

N/A

Clinical Trials (1)

NCT07527767Secondary Use of PARALLEL-HF Data

N/A

A Study to Characterize the Clinical Presentation and Course of Cryptosporidium in Pediatric Partici

Cryptosporidiosis

N/A

Clinical Trials (1)

NCT07716410A Study to Characterize the Clinical Presentation and Course of Cryptosporidium in Pediatric Participants

N/A

A Study of Dosing Patterns and Costs in Patients With Spinal Muscular Atrophy Receiving Disease Modi

Muscular Atrophy, Spinal

N/A

Clinical Trials (1)

NCT07378943A Study of Dosing Patterns and Costs in Patients With Spinal Muscular Atrophy Receiving Disease Modifying Therapies

N/A

Observation & Diagnosis

Pathologic Myopia

N/A

Clinical Trials (1)

NCT03070717High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV)

N/A

MenACWY-CRM

Meningococcal Disease

N/A

Clinical Trials (1)

NCT01452438Safety Surveillance of MenACWY-CRM Vaccine in Children

N/A

patient-centered communication training

Respiratory Tract Infections

N/A

Clinical Trials (1)

NCT00105248Patient Centered Communication Training to Reduce Antibiotic Use in Acute Respiratory Tract Infections

N/A

Novartis Meningococcal ACWY Conjugate Vaccine

Meningococcal Disease

N/A

Clinical Trials (1)

NCT01705379Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older

N/A

Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Optic Neuritis

N/A

Clinical Trials (1)

NCT05017142Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

N/A

Iron chelator

Chronic Iron Overload

N/A

Clinical Trials (1)

NCT05440487Study to Assess Iron Chelation Therapy in Patients With Chronic Iron Overload

N/A

Clinical Pathway for Alzheimer's Disease in China (CPAD)

Mild Cognitive Impairment

N/A

Clinical Trials (1)

NCT01779310Clinical Pathway for Alzheimer's Disease in China (CPAD)

N/A

Study to Identify Factors Influencing Access of Pregnant Women and Their Infants to Local Healthcare

Pregnancy, Newborn Health

N/A

Clinical Trials (1)

NCT01734434Study to Identify Factors Influencing Access of Pregnant Women and Their Infants to Local Healthcare Systems

N/A

Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyol

Tuberous Sclerosis

N/A

Clinical Trials (1)

NCT02325505Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma

N/A

Verion-LenSx

Astigmatism

N/A

Clinical Trials (1)

NCT02763124Pseudophakic Astigmatic Reduction With Verion-LenSx Arcuate Incisions

N/A

Use of Spectral OCT in Combination Therapy

Choroidal Neovascularization

N/A

Clinical Trials (1)

NCT01025063Use of Spectral OCT in Combination Therapy

N/A

Asian Myeloproliferative Neoplasm (MPN) Registry

Myeloproliferative Neoplasm

N/A

Clinical Trials (1)

NCT05882773Asian Myeloproliferative Neoplasm (MPN) Registry

N/A

Blood sample

Thalassemia

N/A

Clinical Trials (1)

NCT01911871Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations

N/A

Femtosecond laser

Intumescent Cataract

N/A

Clinical Trials (1)

NCT02403206Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts

N/A

A Study of Factors That Affect Long-Term Kidney Transplant Function

Kidney Transplant

N/A

Clinical Trials (1)

NCT00270712A Study of Factors That Affect Long-Term Kidney Transplant Function

N/A

Concept Elicitation and Patient Experience Mapping in SA-AKI

Sepsis-associated Acute Kidney Injury

N/A

Clinical Trials (1)

NCT07180238Concept Elicitation and Patient Experience Mapping in SA-AKI

N/A

Upper gastrointestinal endoscopy and Doppler ultrasound

Myeloproliferative Neoplasms (MPN)

N/A

Clinical Trials (1)

NCT01816256Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms

N/A

Home Reported Outcomes in C3G Study

C3 Glomerulopathy

N/A

Clinical Trials (1)

NCT07029542Home Reported Outcomes in C3G Study

N/A

A Study of the Epidemiology and Hospital Management of Patients With PROS in France

PIK3CA-Related Overgrowth Spectrum

N/A

Clinical Trials (1)

NCT07222423A Study of the Epidemiology and Hospital Management of Patients With PROS in France

N/A

Group 1 Donor Specific Regulation

Liver Transplant

N/A

Clinical Trials (1)

NCT01230502Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation

N/A

Lamprene®/Clofazimine

Non-Tuberculous Mycobacterial (NTM) Infections

N/A

Clinical Trials (1)

NCT04334070Lamprene Multiple Patient Program

N/A

Lotrafilcon B contact lenses with added wetting agent

Refractive Errors

N/A

Clinical Trials (1)

NCT03026257Clinical Assessment of a HYDRAGLYDE® Regimen

N/A

Muscle Wasting in Cancer (MWIC)

Cachexia

N/A

Clinical Trials (1)

NCT03191955Muscle Wasting in Cancer (MWIC)

N/A

Onasemnogene Abeparvovec

Spinal Muscular Atrophies

N/A

Clinical Trials (5)

NCT03505099Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2

Phase 3

NCT03837184Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies

Innate Immune Response in COPD

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT02637219Innate Immune Response in COPD

N/A

Cataract Refractive Suite

Cataracts

N/A

Clinical Trials (1)

NCT02974140Cataract Refractive Suite Study

N/A

Change in Ocular Flora Resistance From Repeated Topical Antibiotic Use

Increased Drug Resistance

N/A

Clinical Trials (1)

NCT01181713Change in Ocular Flora Resistance From Repeated Topical Antibiotic Use

N/A

Cardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome Patients

Metabolic Syndrome

N/A

Clinical Trials (1)

NCT00171548Cardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome Patients

N/A

Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Infants Ag

Invasive Group B Streptococcus Disease

N/A

Clinical Trials (1)

NCT02099149Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Infants Aged Less Than 90 Days

N/A

The Living Kidney Donor Safety Study

Living Kidney Donation

N/A

Clinical Trials (1)

NCT00936078The Living Kidney Donor Safety Study

N/A

No vaccine administered; subjects only have blood sampling for immunogenicity

Rabies

N/A

Clinical Trials (1)

NCT01067079Single Center, Open Label, Follow up Study in Subjects Who Previously Received Rabies Vaccine as Simulated Post-Exposure Regimen

N/A

ICS withdrawal

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT02691988Withdrawal of Inhaled Corticosteroids in Primary Care Patients With COPD

N/A

Autologous islet transplantation

Partial Pancreatectomy Due to Benign Pancreatic Neoplasm

N/A

Clinical Trials (1)

NCT01922492Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug.

N/A

transcranial electric stimulation

Mild Cognitive Impairment (MCI)

N/A

Clinical Trials (1)

NCT07092839Non-invasive Deep Brain Stimulation to Enhance Motor Skill Acquisition in Individuals With Mild Cognitive Impairment

N/A

Urinary Biomarkers of the Progression of Alport Kidney Disease

Alport Syndrome

N/A

Clinical Trials (1)

NCT01705132Urinary Biomarkers of the Progression of Alport Kidney Disease

N/A

Interview Prep Quick Facts

Portfolio: 946 approved products, 159 clinical trials

Top TAs: Oncology, Cardiovascular, Neurology

H-1B (2023): 2 approvals

Publications: 227 in PubMed

Open Roles: 866 active jobs

Portfolio Health

Pre-Launch117 (12%)

Launch3 (0%)

Growth11 (1%)

Peak41 (4%)

LOE Approaching184 (19%)

Post-LOE588

Therapeutic Area Focus

Oncology

124 marketed1655 pipeline

Cardiovascular

142 marketed407 pipeline

Neurology

133 marketed314 pipeline

Infectious Diseases

92 marketed296 pipeline

Hiring Trend

Actively Hiring

866

Open Roles

+232

Added

-166

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (17)

2026-07-01

322 employees affected— East Hanover, NJ

2026-05-01

76 employees affected— East Hanover, NJ

2026-04-01

60 employees affected— East Hanover, NJ

2026-03-01

114 employees affected— East Hanover, NJ

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

A comprehensive evaluation of the human Tg32 and Tg276 FcRn transgenic mouse and non-human primate models for predicting antibody pharmacokinetics in human.

mAbs

2026

PMID:42099067

Examining Referral Pathways for Patients with Hematuria: A Real-World Retrospective Analysis.

INHALATION · AEROSOL, METERED

NCT00154362The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.

Phase 4

NCT06851845Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective Study

N/A

NCT04042025Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi

Phase 3

42 marketed266 pipeline

Ophthalmology

89 marketed188 pipeline

Nephrology

22 marketed250 pipeline

Immunology

61 marketed206 pipeline

114 employees affected— East Hanover, NJ

2025-09-01

60 employees affected— East Hanover, NJ

2025-09-01

60 employees affected— East Hanover, NJ

2025-03-12

34 employees affected— CA

2025-03-01

427 employees affected— East Hanover, NJ

2025-03-01

427 employees affected— East Hanover, NJ

2024-11-01

53 employees affected— East Hanover, NJ

2024-11-01

53 employees affected— East Hanover, NJ

2024-07-05

29 employees affected— CA

2024-06-01

96 employees affected— East Hanover, NJ

2024-06-01

96 employees affected— East Hanover, NJ

2024-03-20

680 employees affected— East Hanover, NJ

2023-08-15

— East Hanover, NJ

Source: state DOL filings, aggregated via Big Local News

1 active drug shortage

16 WARN filings filed between August 2023 and July 2026, affecting 2,531+ employees, with East Hanover, NJ as primary impact site (680-person spin-off restructuring in March 2024 followed by 427, 322, and smaller sequential cuts through mid-2026).

Layoff frequency and scale pose significant job-security risk; employment at Novartis carries elevated restructuring exposure relative to stable Big Pharma peers.

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Novartis(NVSEF)

Should You Work at Novartis?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (267)

Key Products by Revenue

Other Products (210)

Pipeline & Clinical Trials

Recent News · Novartis(10)

Open Jobs (866)

Allergy Territory Account Specialist-Long Island / Queens, NY- Overlay

HSE Specialist (Facility Safety)

Principal Scientist, Biomarker Assay Development Bench Scientist

Sr Principal Scientist / Associate Director, Biomarker Assay Development Laboratory

Job Posting Title Dermatology Territory Account Specialist – East Bay, CA

Ultra-Rare Disease Territory Account Specialist – Austin/Houston, TX

Allergy Territory Account Specialist – Detroit and Ann Arbor, MI- Overlay

Discovery Postdoctoral Fellow, Target Biology – Oncology

Clinical Program Leader (CPL)

Neuroscience Territory Account Specialist – Austin / San Antonio

Director, Therapeutic Area Strategy, Neuroscience

Dermatology Territory Account Specialist – Des Moines, IA

Senior Clinical Research Associate (Midwest)

Director, R&D Legal, Americas

Dermatology Territory Account Specialist – Baltimore / Bethesda

Dermatology Regional Director – East

Director, Future Field Engagement Strategy – Metrics & Incentives

Oncology Territory Account Specialist, Solid Tumor – Macon GA

Radioligand Therapies (RLT) Associate Director, Priority Accounts – Kentucky/Tennessee/South Carolina

Senior Administrative Assistant II

Associate Director, AI Foundations Engineering (3 Openings)

Senior Expert Data Science, Scientific Innovation

Director, Analytics Engineering (2 Openings)

Associate Director, Data Reporting Analyst

Head of Adoption and Value Realization

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (17)

Research Publications(10)